Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HMGCR | P04035 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2954181 | 0.94 | TAAR1 (0.56) | TAAR1ACHEMAPTALDH1A1CYP3A4 | |
| SCHEMBL12330214 | 0.90 | TAAR1 (0.48) | TAAR1ACHEMAPTALDH1A1CYP3A4 | |
| SCHEMBL8269049 | 0.88 | TAAR1 (0.52) | TAAR1ACHEMAPTALDH1A1KDM4E | |
| SCHEMBL1912056 | 0.87 | ACHE (0.52) | TAAR1ACHEMAPTALDH1A1CYP3A4 | |
| SCHEMBL1276533 | 0.83 | CYP3A4 (0.59) | ACHEMAPTALDH1A1CYP3A4KDM4E | |
| SCHEMBL3873431 | 0.82 | MAPT (0.47) | TAAR1ACHEMAPTALDH1A1CYP3A4 | |
| SCHEMBL14507701 | 0.82 | TAAR1 (0.48) | TAAR1ACHEMAPTALDH1A1KDM4E | |
| SCHEMBL12326171 | 0.82 | TAAR1 (0.48) | TAAR1ACHEMAPTALDH1A1KDM4E | |
| SCHEMBL3480776 | 0.82 | TAAR1 (0.39) | TAAR1ACHEMAPTALDH1A1CYP3A4 | |
| Ethylamine SCHEMBL6314624 | 0.80 | TAAR1 (0.63) | TAAR1MAPTALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022260163-A1 | COMPOUND OR SALT THEREOF AND PHOTOSENSITIZER | 国立大学法人長崎大学 | 2022-12-15 | — | — | WO | disclosed |
| US-10442779-B2 | Compositions and methods for treating Friedreich's ataxia | FRATAGENE THERAPEUTICS S.R.L. (IT) | 2019-10-15 | — | — | US | disclosed |
| EP-2203161-B1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | UNIV INDIANA RES & TECH CORP (US) | 2018-05-09 | — | — | EP | disclosed |
| US-9957214-B2 | Multifunctional radical quenchers | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-05-01 | — | — | US | disclosed |
| US-9744186-B2 | Substituted gemcitabine aryl amide analogs | NUCORION PHARMACEUTICALS, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| WO-2017007612-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-01-12 | — | — | WO | disclosed |
| US-20160354399-A1 | SUBSTITUTED GEMCITABINE ARYL AMIDE ANALOGS | THE OHIO STATE UNIVERSITY | 2016-12-08 | — | — | US | disclosed |
| US-9447137-B2 | Substituted gemcitabine aryl amide analogs | NUCORION PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9365588-B2 | Benzoxazines as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365588-B2 | Benzoxazines as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-14 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| US-7381842-B2 | Oxime ester photoinitiators | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381842-B2 | Oxime ester photoinitiators | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2008-06-03 | — | — | US | disclosed |
| US-7348032-B2 | Method for extracting antineoplastic components from Bupleurum scorzonerifolium | BUDDHIST TZU CHI GENERAL HOSPITAL (TW) | 2008-03-25 | — | — | US | disclosed |
| US-7348032-B2 | Method for extracting antineoplastic components from Bupleurum scorzonerifolium | BUDDHIST TZU CHI GENERAL HOSPITAL (TW) | 2008-03-25 | — | — | US | disclosed |
| US-20070299073-A1 | Imidazolyl derivatives | IPSEN PHARMA S.A.S. (FR) | 2007-12-27 | — | — | US | disclosed |
| WO-2007144785-A2 | RYANODINE RECEPTOR INHIBITORS AND METHODS RELATING THERETO | UTI LIMITED PARTNERSHIP (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | TAAR1 3870/4885ACHE 3198/4885MAPT 4163/4885 |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | TYMS, TYMP, DPYD | TAAR1 2064/4885ACHE 2568/4885MAPT 2178/4885 |
| US-20070299073-A1 | Imidazolyl derivatives | SSTR5, SSTR3, SSTR2 | TAAR1 111/4885ACHE 3962/4885MAPT 4712/4885 |
| US-10442779-B2 | Compositions and methods for treating Friedreich's ataxia | ATXN10, ATXN2, ATXN2L | TAAR1 4814/4885ACHE 263/4885MAPT 652/4885 |
| US-20160354399-A1 | SUBSTITUTED GEMCITABINE ARYL AMIDE ANALOGS | KRAS, NRAS, GMNN | TAAR1 2659/4885ACHE 3445/4885MAPT 3845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.